Intravenous and local intra-arterial tissue-plasminogen activator in a rabbit model of acute thromboembolic stroke: Angiographic comparison

Advances in Therapy

Volumn 19, Issue 6, 2002, Pages 266-274

  Erdogan, Bulent ^a   Sen, Orhan ^a   Caner, Hakan ^a   Ceviker, Necdet ^b   Baykaner, Kemali ^b   Ilgit, Erhan ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Rabbits; Thromboembolic stroke; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMMON CAROTID ARTERY; COMPARATIVE STUDY; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; FIBRINOLYTIC THERAPY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; RABBIT; RECANALIZATION; REPERFUSION; THROMBOEMBOLISM; ANIMAL; CAROTID ARTERY THROMBOSIS; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION;

ANGIOGRAPHY, DIGITAL SUBTRACTION; ANIMALS; CAROTID ARTERY THROMBOSIS; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; RABBITS; REPERFUSION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0036827504     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02853172     Document Type: Article

References (23)

1. Yepes M, Sandkvist M, Wong MK, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood. 2000;96:569-576.
2. Fisher M, Bogousslavsky J. Further evolution toward effective therapy for acute ischemic stroke. JAMA. 1998;279:1298-1303.
3. Toomey JR, Valocik RE, Koster PF, et al. Inhibition of factor IX (a) is protective in a rat model of thromboembolic stroke. Stroke. 2002;33:578-585.
4. Adams RD, Victor M. Cerebrovascular diseases. In: Principles of Neurology. New York: McGraw-Hill; 1993:669-748.
5. The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
6. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
7. Haefelin CN, Brinker G, Pillekamp UU, Hossmann KA, Hoehn M. Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism. Stroke. 2002;33:1392-1398.
8. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute stroke. JAMA. 1995;274:1017-1025.
9. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. JAMA. 1999;282:2019-2026.
10. Clark WM, Albers GW, Madden KP, Hamilton S, for the Thrombolytic Therapy in Acute Ischemic Stroke Investigators. The rt-PA (alteplase) 0-6-hour acute stroke trial, part A (A0276g). Results of a double blind, placebo-controlled, multicenter study. Stroke. 2000;31:811-816.
11. Philips DA, Davis MA, Fisher M. Selective embolization and clot dissolution with tPA in the internal carotid artery circulation of the rabbit. AJNR. 1988;9:899-902.
12. Hamilton MG, Lee JS, Cummings PJ, Zabramski JM. A comparison of intra-arterial and intravenous tissue type plasminogen activator on autologous emboli in the cerebral circulation of rabbits. Stroke. 1994;25:651-655.
13. Russell D, Madden KP, Clark WM, Zivin JA. Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration. Stroke. 1992;23:388-393.
14. Zeumer H, Freitag HJ, Knospe V. Intravascular thrombolysis in central nervous system cerebrovascular disease. Neuroimag Clin North Am. 1992;2:359-369.
15. Morgenstern LB, Staub L, Chan W, et al. Improving delivery of acute stroke therapy. The TLL Temple Foundation Stroke Project. Stroke. 2002;33:160-166.
16. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized clinical trial. JAMA. 1999;282:2003-2011.
17. Gönner F, Remonda L, Mattle H, et al. Local intra-arterial thrombolysis in acute ischemic stroke. Stroke. 1998;29:1894-1900.
18. Sasaki O, Takeuchi S, Koike T, Koizumi T, Tanaka R. Fibrinolytic therapy for acute embolic stroke: intravenous, intracarotid, and intra-arterial local approaches. Neurosurgery. 1995;36:1309-1310.
19. Theron J, Coskun O, Huet H, Oliveira G, Toulas P, Payelle G. Local intraarterial thrombolysis in the carotid territory. Intervent Neuroradiol. 1996;2:111-126.
20. Lapchak PA, Aaujo DM, Song D, Wei J, Purdy R, Zivin JA. Effects of the spin trap agent disodium-[(tert-butylimino) methyl] benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model. Combination studies with tissue plasminogen activator. Stroke. 2002;33:1665-1670.
21. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31:3034- 3040.
22. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002;33:831-836.
23. Zhang Z, Zhang L, Yepes M, et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation. 2002;106:740-745.